Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Immuncell-LC + temozolomide
- Development stage
- Unknown
- Lead developer
- GC Cell
- Modality
- Cell Therapies, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Immuncell-LC + temozolomide is a combination therapy under investigation primarily for glioblastoma and other cancers. **Immuncell-LC** is an autologous immune cell therapy derived from peripheral blood mononuclear cells; these are cultured ex vivo to generate cytotoxic T lymphocytes and cytokine-induced killer (CIK) cells, intended to stimulate the immune response against tumors. **Temozolomide** is a small molecule oral alkylating agent that methylates DNA to induce tumor cell apoptosis and is a standard treatment for glioblastoma. The combination is being clinically evaluated for improved efficacy and safety relative to temozolomide alone, especially in newly diagnosed glioblastoma[1][3][4][6].
- Brand names
- Temomedac
- Other names
- Immuncell LCTEMODAR
Beyond the preview
Go deeper on Immuncell-LC + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immuncell-LC + temozolomide.